Early Dapagliflozin Administration Cuts Heart Failure Admissions, Study Finds Dr. Prem Aggarwal3 Oct 2024 9:00 AM ISTJapan: A recent study has shed light on the effects of early versus late administration of dapagliflozin in patients suffering from decompensated...
SGLT2 Inhibitors Show Promise in Reducing Heart Plaque Build-up in Diabetes Patients: Study Medha Baranwal24 July 2024 9:15 AM ISTChina: In a recent longitudinal cohort study involving patients with type 2 diabetes mellitus (T2DM), treatment with SGLT2 inhibitors led to...
Type 2 diabetes: Novel SGLT2 inhibitor enavogliflozin shows superior glycemic efficacy over dapagliflozin Medha Baranwal7 Sept 2023 11:30 AM ISTIndia: A recent meta-analysis published in Diabetes & Metabolic Syndrome: Clinical Research & Reviews has shown the superiority of...
SGLT2 inhibitor luseogliflozin bests DPP4 inhibitors among diabetes patients Medha Baranwal15 July 2023 10:30 AM ISTJapan: A recent study published in Diabetes Therapy has shown the efficacy of luseogliflozin (SGLT2 inhibitor) over DPP-4 inhibitors in the...
SGLT2 inhibitors used less frequently in HFrEF patients despite potential CV benefits: JAMA Medha Baranwal24 May 2023 10:30 AM ISTUSA: A recent study published in JAMA Cardiology found low rates of SGLT2 inhibitors for HFrEF (heart failure with reduced ejection fraction) in the...
Empagliflozin promising in hyponatremia induced by Chronic Syndrome of Inappropriate Antidiuresis Dr Kartikeya Kohli10 Feb 2023 11:30 AM ISTSwitzerland: According to clinical research on acid-base and electrolyte disorders, the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
SGLT-2 inhibitors and MRAs combo reduces cardiovascular events in patients with CKD Jacinthlyn Sylvia23 Nov 2022 8:00 PM ISTA new study published in Diabetes Research and Clinical Practice suggests that combination of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and...
Triple Combo therapy not likely to benefit heart failure patients with preserved HF: Circulation Medha Baranwal2 Jun 2022 11:00 AM ISTUSA: The combined benefits of an angiotensin receptor-neprilysin inhibitor (ARNI), a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose...
Empagliflozin retains benefits in 'True' HFpEF Patients Ruchika Sharma3 Dec 2021 5:31 PM ISTEmpagliflozin provides a wide range of benefits in patients with "true" heart failure and preserved ejection fraction (HFpEF) , meaning an LVEF of 50%...
Study compares effectiveness of SGLT2i and GLP-1RA in elderly diabetics MD Bureau15 Feb 2021 7:41 AM ISTSodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are two classes of glucose-lowering...
Canagliflozin may Reduce Risk of Anemia in Diabetic Patients with CKD: Lancet Dr Kartikeya Kohli6 Feb 2021 11:30 AM ISTAnemia is a common accompaniment to diabetes, particularly in those with albuminuria or reduced renal function. In a study published in The LANCET...
SGLT-2 inhibitors significantly lower risk of Atrial Fibrillation: Study Dr Satabdi Saha4 Feb 2021 9:45 AM ISTA recent review published in Diabetes, Obesity & Metabolism and based on a clinical trial suggests that there is a significantly lower risk of...
